Vyleesi® product results: 14% growth in prescriptions dispensed over prior quarter – 6 consecutive quarters of double digit growth.
Click here to learn more ›

September 2015

Preclinical Data on PL-3994 for Heart Failure and Resistant Hypertension Presented at 2015 Heart Failure Society of America Annual Meeting

CRANBURY, N.J., Sept. 28, 2015 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today announced that a poster entitled “Conditional cardiomyocyte-restricted Corin KO mice demonstrate enhanced cardiac hypertrophy and pro-fibrotic gene activation in response to …

Preclinical Data on PL-3994 for Heart Failure and Resistant Hypertension Presented at 2015 Heart Failure Society of America Annual Meeting Read More »

Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2015 Results

CRANBURY, N.J., Sept. 21, 2015 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today announced results for its fourth quarter and fiscal year ended June 30, 2015.  Fiscal Year Ended June 30, 2015 and Recent …

Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2015 Results Read More »

Palatin Technologies and Richter Terminate License Agreement for Bremelanotide for Female Sexual Dysfunction

CRANBURY, N.J., Sept. 21, 2015 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today announced that the Company and Gedeon Richter (Richter) mutually and amicably agreed to terminate the license and collaboration agreement for bremelanotide …

Palatin Technologies and Richter Terminate License Agreement for Bremelanotide for Female Sexual Dysfunction Read More »

Palatin Technologies, Inc. To Report Fourth Quarter Fiscal Year End 2015 Results

CRANBURY, N.J., Sept. 16, 2015 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN) will announce its fourth quarter, fiscal year end 2015 operating results on Monday, September 21, 2015 before the open of the U.S. financial markets. Palatin will also conduct a conference call and live audio webcast hosted by its executive management team on …

Palatin Technologies, Inc. To Report Fourth Quarter Fiscal Year End 2015 Results Read More »

Scroll to Top